Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

Urogen, UGN-102 stage 3 stage, 18-month response time for a recurrent low-level intermediate-risk research treatment (Dor) 80.6%, 80.6%



Urogen, UGN-102 stage 3 stage, 18-month response time for a recurrent low-level intermediate-risk research treatment (Dor) 80.6%, 80.6%



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *